News & Insights

Recognition

May 25, 2017

New England VC Association Names King & Spalding Transaction Deal of the Year


BOSTON, May 25, 2017 — The New England Venture Capital Association has named a King & Spalding deal — the Jounce-Celgene strategic collaboration worth up to $2.5 billion — as the Healthcare and Life Sciences Deal of the Year at its annual NEVY awards.

King & Spalding advised Cambridge, Mass.-based Jounce Therapeutics on its collaboration with Celgene Corp. focused on developing and commercializing innovative immuno-oncology treatments for patients with cancer in July 2016. Under the terms of the collaboration, Celgene made an upfront payment to Jounce of $225 million. Aggregate payments for development, regulatory and commercial milestones could potentially be $2.3 billion in total across all programs reaching commercialization.

The NEVY awards were held Wednesday at Boston’s House of Blues, and winners were chosen by a panel of members of New England’s venture community, taking into account public opinion and the winners’ impact on the areas venture ecosystem.

The King & Spalding team on this deal included San Francisco-based partner Tom Duley and senior associate Stephen Abreu, both of whom are corporate lawyers focused on the life sciences industry. Additional assistance was provided by partners Elaine Tseng, Jonathan Talansky, Peter Todaro and Laura Bushnell.

About King & Spalding

Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 1,000 lawyers in 19 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.